MNPR – monopar therapeutics inc. (US:NASDAQ)
Stock Stats
News
Monopar Therapeutics (MNPR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $100.00 price target on the stock.
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16 [Seeking Alpha]
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Form 4 Monopar Therapeutics For: Mar 31 Filed by: Robinson Chandler
Form 4 Monopar Therapeutics For: Mar 31 Filed by: Cittadine Andrew
Form 10-K/A Monopar Therapeutics For: Dec 31
Form 8-K Monopar Therapeutics For: Mar 27
Form 10-K Monopar Therapeutics For: Dec 31
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.